



Notification of Recalculated 340B Prices

BioMarin Pharmaceutical Inc. (“BioMarin”) has recently recalculated 340B ceiling prices for the NDCs references below for the time period of Q1 2019 – Q4 2020.

NDC	Product Description
68135-0020-01	NAGLAZYME 1MG/ML INJ
68135-0058-89	PALYNZIQ .5 mL in 1 SYRINGE
68135-0058-90	PALYNZIQ 2.5MG/0.5ML INJ,SYR,0.5ML
68135-0100-01	VIMIZIM 1MG/ML INJ,SOLN,5ML
68135-0300-02	KUVAN 100MG TAB
68135-0301-11	KUVAN 1 POWDER, FOR SOLUTION in 1 PACKET
68135-0301-22	KUVAN 100MG/PKT PWDR,ORAL
68135-0482-10	KUVAN 1 POWDER, FOR SOLUTION in 1 PACKET
68135-0482-11	KUVAN 500MG/PKT PWDR,ORAL
68135-0673-39	PALYNZIQ 1 mL in 1 SYRINGE
68135-0673-40	PALYNZIQ 20MG/ML INJ,SYR,1ML
68135-0673-45	PALYNZIQ 20MG/ML INJ,SYR,1ML
68135-0756-19	PALYNZIQ .5 mL in 1 SYRINGE
68135-0756-20	PALYNZIQ 10MG/0.5ML INJ,SYR,0.5ML
68135-0811-02	BRINEURA 30MG/ML INJ,KIT

BioMarin has used chargeback data to identify covered entities that may be eligible for a potential refund based on the recalculated 340B ceiling prices and to identify potential payment amounts to affected 340B covered entities. BioMarin will contact any 340B covered entity that may be owed a refund. BioMarin is not seeking repayment where a 340B covered entity paid a lower price than the recalculated 340B ceiling price. In the meantime, if a Covered Entity would like to contact BioMarin regarding this notice, please email the company at 340B@bmrn.com.

BioMarin has asked the Health Resources and Services Administration (“HRSA”) to post this Notice on the HRSA’s public website to ensure transparency to all 340B covered entities regarding the ceiling price recalculations for all NDCs identified above and to offer a refund to any of the 340B covered entities that may have purchased the above NDCs during the relevant time periods.